Quarterly ResultMay 11, 2026, 09:07 AM
MAIA Biotech Q1 Net Loss $(6.37)M; Cash $34.41M from Public Offering
AI Summary
MAIA Biotechnology reported a net loss of $6.37 million for the first quarter of 2026, an increase from $4.52 million in the prior year, though net loss per share improved to $(0.14) from $(0.16). The company significantly strengthened its liquidity, with cash increasing to $34.41 million at March 31, 2026, from $8.66 million at December 31, 2025, primarily driven by $33.01 million in proceeds from a confidentially marketed public offering. Operating expenses continued to rise, reflecting increased research and development and general and administrative costs.
Key Highlights
- Net loss for Q1 2026 was $(6,369,652), compared to $(4,517,259) in Q1 2025.
- Net loss per share improved to $(0.14) in Q1 2026 from $(0.16) in Q1 2025.
- Cash balance increased to $34,413,110 at March 31, 2026, from $8,658,031 at December 31, 2025.
- Received $33,008,813 in proceeds from a confidentially marketed public offering.
- Research and development expenses rose to $3,525,097 from $3,197,532 year-over-year.
- General and administrative expenses increased to $3,424,832 from $2,227,899 year-over-year.
- Net cash used in operating activities was $(5,311,328) for the quarter.
- Working capital stood at $28,992,690 at March 31, 2026.